Case Report: Unclassified Renal Cell Carcinoma With Medullary Phenotype and SMARCB1/INI1 Deficiency, Broadening the Spectrum of Medullary Carcinoma

Autor: Marina Valeri, Miriam Cieri, Grazia Maria Elefante, Camilla De Carlo, Noemi Rudini, Giovanni Lughezzani, Nicolò Maria Buffi, Luigi Maria Terracciano, Piergiuseppe Colombo

Publikováno v: Frontiers in Medicine, Vol 9 (2022)

Renal medullary carcinoma (RMC) is a rare entity with poor prognosis bearing inactivating genomic alterations in SMARCB1/INI1 resulting in the loss of expression of INI1 and occurring in young patients with sickle cell trait or sickle cell disease. R

Externí odkaz: https://doaj.org/article/6e06f0b7ae9745bda942104d28dd3ad7

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Clinical Characteristics, Management, and Outcomes of Patients with Renal Medullary Carcinoma: A Single-center Retrospective Analysis of 135 Patients.

Autor: Lebenthal JM; Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kontoyiannis PD; The University of Texas Health Science Center at Houston, Houston, TX, USA., Hahn AW; Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lim ZD; Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Rao P; Department of Pathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Cheng JP; Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chan B; Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Daw NC; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sheth RA; Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Karam JA; Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Translational Molecular Pathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tang C; Department of Translational Molecular Pathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tannir NM; Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: ntannir@mdanderson.org., Msaouel P; Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Translational Molecular Pathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA. Electronic address: pmsaouel@mdanderson.org.

Publikováno v: European urology oncology [Eur Urol Oncol] 2024 Jul 15. Date of Electronic Publication: 2024 Jul 15.